

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1 - 15. (Canceled)

Claims 16 - 18. (Canceled)

Claim 19. (Canceled)

Claims 20 - 30. (Canceled)

Claims 31 - 33. (Canceled)

Claims 34 - 60. (Canceled)

61. (New) A controlled release pharmaceutical formulation comprising a matrix, said matrix comprising:

- a) a fatty component;
- b) a hydrophilic component dispersed within the matrix; and
- c) a clarithromycin component, or derivative thereof, dispersed within the matrix,

wherein the fatty component, hydrophilic component, and clarithromycin component are combined under conditions suitable for generating the matrix, and wherein the matrix provides a controlled release formulation for the once daily administration of clarithromycin.

62. (New) The pharmaceutical formulation of claim 61, wherein the fatty component comprises 10-36 weight percent of the formulation.
63. (New) The pharmaceutical formulation of claim 61, wherein the hydrophilic component comprises about 5-18 weight percent of the formulation.
64. (New) The pharmaceutical formulation of claim 61, wherein the clarithromycin component comprises at least about 40 weight percent of the formulation.
65. (New) The pharmaceutical formulation of claim 61, wherein the fatty component is a sustained released component that provides sustained release of the clarithromycin or clarithromycin derivative, and wherein the hydrophilic component forms a viscous layer in an aqueous medium through which the clarithromycin or clarithromycin derivative diffuses upon solubilization thereby effective to provide controlled release of the clarithromycin or clarithromycin derivative over about a twenty-four hour period.
66. (New) The pharmaceutical formulation of claim 61, wherein the fatty component is selected from the group consisting of triglycerides of higher saturated fatty acids, hydrogenated oils and mixtures thereof.
67. (New) The pharmaceutical formulation of claim 61, wherein the fatty component is behenic acid or glyceryl behenate, or a combination thereof.
68. (New) The pharmaceutical formulation of claim 61, wherein the hydrophilic component is an alkyl-substituted cellulose ether, xanthan gum, guar gum, or acacia, or any combination thereof.
69. (New) The pharmaceutical formulation of claim 68, wherein the alkyl-substituted cellulose ether is hydroxypropyl methylcellulose.

70. (New) The pharmaceutical formulation of claim 69, wherein the hydroxypropyl methylcellulose is low viscosity hydroxypropyl methylcellulose.

71. (New) The pharmaceutical formulation of claim 70, wherein the hydroxypropyl methylcellulose has a viscosity of about 15 cP.

72. (New) The pharmaceutical formulation of claim 61, further comprising a surfactant.

73. (New) The pharmaceutical formulation of claim 72, wherein the surfactant comprises sodium docusate.

74. (New) The pharmaceutical formulation of claim 61, further comprising a pH modulator.

75. (New) The pharmaceutical formulation of claim 74, wherein the pH modulator comprises a phosphate buffer.

76. (New) The pharmaceutical formulation of claim 61 in tablet form.

77. (New) The pharmaceutical formulation of claim 76, wherein the tablet is coated.

78. (New) The pharmaceutical formulation of claim 77, wherein the coating is an acid-resistant coating.

79. (New) The pharmaceutical formulation of claim 78, wherein the coating comprises a mixture of HPMC and HPC.

80. (New) A method for producing a controlled release pharmaceutical formulation, the method comprising:

- a) forming a matrix comprising:
 - i) a fatty component comprising about 10-36 weight percent of the formulation;
 - ii) a hydrophilic component comprising about 5-18 weight percent of the formulation;
 - iii) a clarithromycin component, or derivative thereof, comprising at least about 40 weight percent of the formulation,

wherein the components are combined to allow the fatty component to form the matrix and wherein the hydrophilic component and the clarithromycin component are dispersed within the matrix; and

- b) compressing the matrix into tablet form.

81. (New) The method of claim 80, further comprising sieving the matrix prior to compressing the matrix into tablet form.